U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Transformed T-cell Non-Hodgkin Lymphoma

MedGen UID:
1720528
•Concept ID:
C5237461
•
Neoplastic Process

Definition

An indolent T-cell non-Hodgkin lymphoma which has undergone histologic transformation to an aggressive T-cell non-Hodgkin lymphoma and has become resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Transformed T-cell Non-Hodgkin Lymphoma

Professional guidelines

PubMed

Second-line treatment with CAR T-cell therapy for large B-cell lymphoma.
Lutfi F, Patel A, Mehta J, Goyal A, Dahiya S
Clin Adv Hematol Oncol 2023 Apr;21(4):170-178. PMID: 37039724
Psychosocial care for children receiving chimeric antigen receptor (CAR) T-cell therapy.
Steineck A, Wiener L, Mack JW, Shah NN, Summers C, Rosenberg AR
Pediatr Blood Cancer 2020 May;67(5):e28249. Epub 2020 Mar 11 doi: 10.1002/pbc.28249. PMID: 32159278Free PMC Article
Mechanisms and management of refractory coeliac disease.
van Gils T, Nijeboer P, van Wanrooij RL, Bouma G, Mulder CJ
Nat Rev Gastroenterol Hepatol 2015 Oct;12(10):572-9. Epub 2015 Sep 8 doi: 10.1038/nrgastro.2015.155. PMID: 26347156

Recent clinical studies

Etiology

Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis.
Kelkar AH, Cliff ERS, Jacobson CA, Abel GA, Dijk SW, Krijkamp EM, Redd R, Zurko JC, Hamadani M, Hunink MGM, Cutler C
Ann Intern Med 2023 Dec;176(12):1625-1637. Epub 2023 Dec 5 doi: 10.7326/M22-2276. PMID: 38048587
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS; TRANSFORM Investigators
Lancet 2022 Jun 18;399(10343):2294-2308. doi: 10.1016/S0140-6736(22)00662-6. PMID: 35717989
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T
Lancet 2020 Sep 19;396(10254):839-852. Epub 2020 Sep 1 doi: 10.1016/S0140-6736(20)31366-0. PMID: 32888407
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS
Lancet Oncol 2019 Jan;20(1):31-42. Epub 2018 Dec 2 doi: 10.1016/S1470-2045(18)30864-7. PMID: 30518502Free PMC Article
CAR T cell therapy for B-cell lymphomas.
Chavez JC, Locke FL
Best Pract Res Clin Haematol 2018 Jun;31(2):135-146. Epub 2018 Apr 11 doi: 10.1016/j.beha.2018.04.001. PMID: 29909914Free PMC Article

Diagnosis

CAR T-cell Therapy for Diffuse Large B-cell Lymphoma in Canada: A Cost-Utility Analysis.
Masucci L, Tian F, Tully S, Feng Z, McFarlane T, Chan KKW, Wong WWL
Med Decis Making 2024 Apr;44(3):296-306. Epub 2024 Mar 14 doi: 10.1177/0272989X241234070. PMID: 38486447Free PMC Article
Targeting the cGAS-STING Pathway Inhibits Peripheral T-cell Lymphoma Progression and Enhances the Chemotherapeutic Efficacy.
Lu X, Wang S, Hua X, Chen X, Zhan M, Hu Q, Cao L, Wu Z, Zhang W, Zuo X, Gui R, Fan L, Li J, Shi W, Jin H
Adv Sci (Weinh) 2024 Mar;11(10):e2306092. Epub 2023 Dec 25 doi: 10.1002/advs.202306092. PMID: 38145335Free PMC Article
Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma.
De Coninck S, De Smedt R, Lintermans B, Reunes L, Kosasih HJ, Reekmans A, Brown LM, Van Roy N, Palhais B, Roels J, Van der Linden M, Van Dorpe J, Ntziachristos P, Van Delft FW, Mansour MR, Pieters T, Lammens T, De Moerloose B, De Bock CE, Goossens S, Van Vlierberghe P
Haematologica 2024 May 1;109(5):1373-1384. doi: 10.3324/haematol.2023.283981. PMID: 37941480Free PMC Article
Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis.
Kelkar AH, Cliff ERS, Jacobson CA, Abel GA, Dijk SW, Krijkamp EM, Redd R, Zurko JC, Hamadani M, Hunink MGM, Cutler C
Ann Intern Med 2023 Dec;176(12):1625-1637. Epub 2023 Dec 5 doi: 10.7326/M22-2276. PMID: 38048587
Infective dermatitis.
Trope BM, Lenzi ME
Clin Dermatol 2009 May-Jun;27(3):281-4. doi: 10.1016/j.clindermatol.2008.10.007. PMID: 19362690

Therapy

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS; TRANSFORM Investigators
Lancet 2022 Jun 18;399(10343):2294-2308. doi: 10.1016/S0140-6736(22)00662-6. PMID: 35717989
Recent advances in CAR-T cell engineering.
Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, Gao L, Wen Q, Zhong JF, Zhang C, Zhang X
J Hematol Oncol 2020 Jul 2;13(1):86. doi: 10.1186/s13045-020-00910-5. PMID: 32616000Free PMC Article
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K
N Engl J Med 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607. PMID: 32023374Free PMC Article
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS
Lancet Oncol 2019 Jan;20(1):31-42. Epub 2018 Dec 2 doi: 10.1016/S1470-2045(18)30864-7. PMID: 30518502Free PMC Article
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY
N Engl J Med 2017 Dec 28;377(26):2531-2544. Epub 2017 Dec 10 doi: 10.1056/NEJMoa1707447. PMID: 29226797Free PMC Article

Prognosis

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ
J Clin Oncol 2021 Jun 20;39(18):1959-1970. Epub 2021 Mar 19 doi: 10.1200/JCO.20.03175. PMID: 33739857Free PMC Article
Mechanisms of and approaches to overcoming resistance to immunotherapy.
Schultz L, Gardner R
Hematology Am Soc Hematol Educ Program 2019 Dec 6;2019(1):226-232. doi: 10.1182/hematology.2019000018. PMID: 31808880Free PMC Article
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS
Lancet Oncol 2019 Jan;20(1):31-42. Epub 2018 Dec 2 doi: 10.1016/S1470-2045(18)30864-7. PMID: 30518502Free PMC Article
CAR T cell therapy for B-cell lymphomas.
Chavez JC, Locke FL
Best Pract Res Clin Haematol 2018 Jun;31(2):135-146. Epub 2018 Apr 11 doi: 10.1016/j.beha.2018.04.001. PMID: 29909914Free PMC Article
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY
N Engl J Med 2017 Dec 28;377(26):2531-2544. Epub 2017 Dec 10 doi: 10.1056/NEJMoa1707447. PMID: 29226797Free PMC Article

Clinical prediction guides

Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis.
Kelkar AH, Cliff ERS, Jacobson CA, Abel GA, Dijk SW, Krijkamp EM, Redd R, Zurko JC, Hamadani M, Hunink MGM, Cutler C
Ann Intern Med 2023 Dec;176(12):1625-1637. Epub 2023 Dec 5 doi: 10.7326/M22-2276. PMID: 38048587
Leukapheresis for CAR-T cell production and therapy.
Pessach I, Nagler A
Transfus Apher Sci 2023 Dec;62(6):103828. Epub 2023 Oct 11 doi: 10.1016/j.transci.2023.103828. PMID: 37838564
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS; TRANSFORM Investigators
Lancet 2022 Jun 18;399(10343):2294-2308. doi: 10.1016/S0140-6736(22)00662-6. PMID: 35717989
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ
J Clin Oncol 2021 Jun 20;39(18):1959-1970. Epub 2021 Mar 19 doi: 10.1200/JCO.20.03175. PMID: 33739857Free PMC Article
Mechanisms of and approaches to overcoming resistance to immunotherapy.
Schultz L, Gardner R
Hematology Am Soc Hematol Educ Program 2019 Dec 6;2019(1):226-232. doi: 10.1182/hematology.2019000018. PMID: 31808880Free PMC Article

Recent systematic reviews

A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells.
Fergusson NJ, Adeel K, Kekre N, Atkins H, Hay KA
Front Immunol 2023;14:1178403. Epub 2023 Apr 27 doi: 10.3389/fimmu.2023.1178403. PMID: 37180149Free PMC Article
Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia.
Grover P, Veilleux O, Tian L, Sun R, Previtera M, Curran E, Muffly L
Blood Adv 2022 Mar 8;6(5):1608-1618. doi: 10.1182/bloodadvances.2020003482. PMID: 34610109Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...